We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CuraGen (CRGN)
An SI Board Since March 1998
Posts SubjectMarks Bans Symbol
478 35 0 CRGN
Emcee:  Superhawk Type:  Unmoderated
CuraGen is a biotechnology company pioneering the systematic
application of genomics to accelerate the discovery & development
of therapeutic and agricultural products.

Of all of the biotechnology sub-disciplines in terms of return on
investment, genomics is purported to have one, if not the highest
potential. In layman's language, CuraGen thinks they can speed up
the tedious, therefore expensive, processes of finding genes which
code for proteins involved in disease processes. They claim they
have developed automated, "high-throughput" means of also
discovering chemicals which can interact with these proteins,
thereby altering a disease process. They propose to computerize
the whole, complicated database, and make money by charging
subscription fees, by engaging in research collaborations, and by
retaining product rights for revenues and royalties.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
478yep! 1. Celldex acquires CuraGen for $94.5M By Maureen Martino Comment | Forwamlkr-6/2/2009
477Thanks for marking that 0.67, three months ago. Munched by Celldex, and tradingscaram(o)uche-5/29/2009
476Strategic alternative: $0.67 CuraGen's Board of Directors to Evaluate Stratmlkr-2/23/2009
475CuraGen Announces Top-Line Phase II Results on Velafermin Thursday October 11, 7nigel bates-10/11/2007
474CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical DeveMike McFarland-8/6/2007
473OT that was a pretty good call, crgn down 10% and exel up 7% in the past few dayMike McFarland-6/26/2007
472Off 50% this year so far, don't ask me when it is due for a bounce <i>Mike McFarland-6/21/2007
471Cashboy; But what has CRGN got left? I was in for 454 and when that went away..Steve Lokness-6/21/2007
470You did well to sell your crgn, it has been falling pretty fast the past couple Mike McFarland-6/21/2007
469Well Crap! Is right. Sold the last of my CRGN. Gosh this is sad. What can Roche Steve Lokness-5/3/2007
468> I'm sure Roche are very happy indeed. I hope so. In retrospect, maybeCrazyPete-3/30/2007
467>>Is CRGN so desperate for liquidity...<< Undoubtedly. >>...tnigel bates-3/30/2007
466Well crap. Any comments on the logic of this deal? I'm familiar with the tCrazyPete-3/29/2007
465CuraGen Announces Definitive Agreement to Sell 454 Life Sciences to Roche Thursdnigel bates-3/29/2007
464[PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following extuck-2/20/2007
463[HDAC inhibitors (PXD101) and Velcade vs head and neck cancer] >>Mol Canctuck-1/24/2007 New newsletter from GenomewebMike McFarland-1/12/2007
461454 sure getting a lot of ink lately; steveSteve Lokness-1/10/2007
460CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial nigel bates-12/14/2006
459Thanks. That certainly fills up my spare reading time!tom pope-11/24/2006
458Actually, there is some discussion of this. Check out the (freebie) paper at - nnigel bates-11/24/2006
457No examination of how many of the variations are ethnically based.tom pope-11/23/2006
456New study underlines the potential importance of whole genome sequencing: Messanigel bates-11/23/2006
455CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trnigel bates-11/16/2006
454454 Life Sciences and Max Planck Publish Sequence of One Million Base Pairs of Nnigel bates-11/15/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):